AI accelerates drug formulation through predictive modelling
Predictive models are transforming drug development, allowing teams to respond faster and more efficiently while optimising resources across formulation and testing stages.
Low solubility and poor bioavailability remain major hurdles in small-molecule drug development, often preventing promising candidates from reaching clinical trials. Traditional trial-and-error methods are time-consuming and depend heavily on the limited availability of active pharmaceutical ingredients (APIs).
AI and machine learning now provide predictive models that anticipate solubility, permeability and systemic exposure. These tools let scientists prioritise high-impact experiments while conserving valuable material.
Digital platforms combine predictive algorithms with stability testing to guide excipient and technology selection. AI can simulate molecular interactions and dose scenarios, helping teams identify risks early and refine first-in-human doses safely.
End-to-end AI/ML workflows integrate data, modelling and manufacturing insights. However, this accelerates development timelines, lowers the risk of late-stage reformulations and connects early formulation choices directly to clinical and manufacturing outcomes.
While AI enhances efficiency and precision, it does not replace human expertise. It amplifies formulation scientists’ work, freeing them to focus on innovative design, problem-solving and delivering high-quality therapies to patients more rapidly.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!